Podcasts about Emory University

Texas surgeon Dr. Elisabeth Potter says UnitedHealthcare stopped her mid-surgery to question if the patient's procedure was necessary – despite the fact the patient was already on the operating table. Dr. Potter was even threatened with legal action after sharing her astonishing story on social media. The health insurance giant denies that it would ever ask a doctor to interrupt care. But this incident follows an alarming pattern with UnitedHealthcare. According to Daily Mail, “UnitedHealthcare has also been accused of using an AI program with a 90 percent error rate to deny claims.” “Without insurance,” the Mail says the surgery being performed by Dr. Potter “costs anywhere from $30,000 to $50,000.” The Mail also reports a spokesperson from UnitedHealthcare claimed “There are no insurance related circumstances that would require a physician to step out of surgery… We did not ask nor would ever expect a physician to interrupt patient care to answer a call.” Dr. Elisabeth Potter details UnitedHealthcare's legal threats against her for speaking out. Dr. Eric Weiss shares his pioneering work in stem cell therapy for autism, drawing from his son's journey and a suppressed CDC study showing a 1135% autism increase linked to thimerosal in vaccines. Dr. Elisabeth Potter is a board-certified plastic surgeon who earned her MD from Emory University and completed a fellowship at MD Anderson. She specializes in natural breast reconstruction, performing over 1,000 DIEP flap surgeries. Formerly a regulatory analyst of FDA law, she monitors BIA-ALCL risks. Follow at https://x.com/epottermd Dr. Eric Weiss is board-certified in plastic surgery and a leader in regenerative medicine. Founder of North Florida Stem Cells Clinic, he treats autism with stem cell therapy. He co-authored Educating Marston, a memoir about his son's autism journey. Follow at https://instagram.com/northfloridastemcells 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/sponsors⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠• FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • VSHREDMD – Formulated by Dr. Drew: The Science of Cellular Health + World-Class Training Programs, Premium Content, and 1-1 Training with Certified V Shred Coaches! More at https://drdrew.com/vshredmd • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠) and Susan Pinsky (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/firstladyoflov⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠e⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Learn more about your ad choices. Visit megaphone.fm/adchoices

Shots fired in Atlanta, and police believe the gunman was targeting the Centers for Disease Control.  A police officer was killed during the incident on the campus of Emory University in Atlanta, authorities said tonight. Plus, the President names a date and place for his summit with Putin.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Pierre Thomas has the latest on the active shooting that unfolded in Atlanta near the CDC headquarters and Emory University's campus, and left one police officer dead; Mary Bruce has details on Pres. Trump announcing that he will meet with Russia's Pres. Vladimir Putin next Friday in Alaska; Trevor Ault has details on the fast-moving wildfires in the West forcing thousands to evacuate, including the Canyon Fire north of L.A. that has exploded in size; and more on tonight's broadcast of World News Tonight with David Muir. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Police Rush to Emory University After Scary Incident! Breaking news as an active shooter situation unfolds at Emory College in Georgia, resulting in an emergency response. Stay tuned for live updates as this situation develops. At approximately 4:50 PM an active shooter fired numerous shots in the vicinity of the CDC building in Atlanta. A Dekalb County Police officer was critically wounded and rushed to an area hospital. The active shooter is deceased.

President Trump confirms that he is about to meet with Putin here in the United States and discuss swapping territories. Plus, a massive police presence on the campus of Emory University in Atlanta after reports of a shooter.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Today, I'm joined by Sean Glaze, and we're talking about how to fix the real issues holding your team back. Sean is a sought-after leadership and workplace culture speaker who gained valuable insights on turning talent into teamwork as a successful basketball coach – and now he travels around the country to share those actionable lessons. Sean's engaging conference leadership, keynotes, and custom team building programs have helped clients like Cisco, John Deere, the CDC, and Emory University to increase collaboration, boost productivity, and build Sticky Cultures that inspire more profitable teamwork. Sean's books, Rapid Teamwork, What Effective Leaders DO, The 10 Commandments of Winning Teammates, and Staying Coachable are entertaining parables that accelerate the growth of leaders and teams. I'm excited to have him on the show to learn more about how to fix the real issues holding your team back. Show resources: Sean Glaze's website Sean Glaze on LinkedIn Tool Box Stuff Sponsors: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cadre of Men⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Farrow Skin Care⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Salty Sailor Coffee Company⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Leader Connect⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Qualified Leadership Series⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ____ Get all of Jon Rennie's bestselling leadership books for 15% off the regular price today! ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠HERE Learn more about your ad choices. Visit megaphone.fm/adchoices

AP correspondent Ben Thomas reports a suspected gunman and a police officer were killed in shooting near the CDC and Emory University in Atlanta.

A shooting suspect and one DeKalb County police officer are dead after an active shooter situation played out near the campuses of the CDC and Emory University; Class action lawsuit seeks to reverse state's denial of transgender care to inmates; and drinking and flushing are about to cost more in Fulton County. See omnystudio.com/listener for privacy information.

Live, Local, Topical, and Authentic where you provide the balance to our content. Tonight, in Hour 2, Shelley talks to Georgia State Sentor Jason Esteves about his run for Govenor, and speaks about the shooting near Emory University and much more. Listen LIVE weeknights 7pm-9pm on 95.5 WSB

Kadie DiGiuseppe delivers the latest news on the active shooter at Emory University, President Trump confirming his upcoming meeting with Vladimir Putin and the Israeli military continuing to build up troops around Gaza on 8/9/25.

Causes for the youth’s attraction to socialism. Remembering the 51st Anniversary of President Nixon’s resignation from the presidency. The active shooter incident at Emory University in Atlanta, Georgia. A listener call-in commentary on the similarities between Presidents Nixon and Trump and anger. Salem Phoenix General Manager Mark Durkin joins the show to talk about 960 The Patriot’s ongoing donation campaign with PreBorn! To contribute go to 960thepatriot.com today.See omnystudio.com/listener for privacy information.

Dems comply with outrageous redistricting stunts. Shooter reported near Emory University. Trump, Putin will hold first in-person meeting.See omnystudio.com/listener for privacy information.

Dems comply with outrageous redistricting stunts. Shooter reported near Emory University. Trump, Putin will hold first in-person meeting.See omnystudio.com/listener for privacy information.

Dems comply with outrageous redistricting stunts. Shooter reported near Emory University. Trump, Putin will hold first in-person meetingSee omnystudio.com/listener for privacy information.

Dems comply with outrageous redistricting stunts. Shooter reported near Emory University. Trump, Putin will hold first in-person meeting.See omnystudio.com/listener for privacy information.

Active shooter situation near the campus of Emory University in Atlanta; reports of shots fired at a building housing the CDC. President Trump to meet with Russian President Putin in Alaska on August 15. Firefighters make progress on Canyon wildfire California wildfire north of Los Angeles. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Suneal Bedi, associate professor of business law and ethics at Indiana University, and Todd Haugh, also associate professor of business law and ethics at Indiana University, join the Business Scholarship Podcast to discuss their article Retheorizing Corporate Compliance. This episode is hosted by Andrew Jennings, associate professor of law at Emory University, and was edited by Dean Saridakis, a law student at Emory University.

Sixty years ago today, President Lyndon B. Johnson signed the 1965 Voting Rights Act, saying “The denial of the right to vote, is still a deadly wrong and the time for injustice has gone.” Today, we look back on the landmark legislation and the challenges voting rights see today. Joining Rose Scott for today’s special call-in edition of “Closer Look,” we’re joined by Andra Gillespie, Associate Professor of Political Science and Director of the James Weldon Johnson Institute at Emory University. Also, Dr. Clarissa Myrick-Harris White, a Professor of Africana Studies at Morehouse College and co-founder of the college’s Black Men’s Research Institute and co-principal investigator for the Morehouse Movement, Memory, and Justice.See omnystudio.com/listener for privacy information.

This Day in Legal History: Voting Rights ActOn August 6, 1965, President Lyndon B. Johnson signed the Voting Rights Act into law, marking a pivotal moment in American legal and civil rights history. The legislation aimed to enforce the Fifteenth Amendment by prohibiting racial discrimination in voting, especially in the southern states where such practices were deeply entrenched. The Act outlawed literacy tests and other mechanisms that had been used for decades to suppress the Black vote. It also authorized federal oversight of voter registration and election procedures in jurisdictions with histories of discrimination.The law came in the wake of sustained activism, including the Selma to Montgomery marches and the brutal attack on peaceful demonstrators in what became known as “Bloody Sunday.” Johnson, in a powerful address to Congress, tied the moral imperative of the Act to the nation's founding ideals, declaring that “it is wrong—deadly wrong—to deny any of your fellow Americans the right to vote.” Within months of the Act's passage, hundreds of thousands of Black Americans were registered to vote, reshaping political representation across the South.The Voting Rights Act has since been amended and interpreted by courts, with key provisions reauthorized multiple times. However, in Shelby County v. Holder (2013), the Supreme Court invalidated the formula used to determine which jurisdictions required federal oversight, significantly weakening the Act's enforcement mechanism. This decision opened the door to new state laws that voting rights advocates argue disproportionately affect minority voters.Legal scholars and civil rights lawyers continue to debate the future of the Act, with efforts ongoing to restore and update its protections. The Voting Rights Act of 1965 remains one of the most consequential civil rights statutes in American history, transforming the legal landscape of democratic participation.Ghislaine Maxwell, convicted in 2021 for aiding Jeffrey Epstein in sexually abusing minors, is opposing the U.S. government's attempt to release transcripts from the grand jury that indicted her. Her legal team argues that public disclosure could irreparably damage her reputation and complicate a potential retrial, especially as she seeks to overturn her conviction at the U.S. Supreme Court. They claim the grand jury testimony is incomplete and lacks the scrutiny of cross-examination. The Department of Justice, citing public interest, requested permission from two Manhattan judges to release the material, prompting responses from Maxwell's lawyers, Epstein's estate, and alleged victims.President Donald Trump recently pushed for the release of the documents, seeking to address criticism from both allies and opponents about the handling of the Epstein-Maxwell case. Trump's Justice Department acknowledged that a rumored Epstein client list does not exist, which disappointed some supporters. While Epstein's estate took no stance on the release, attorneys for victims advocated for limited disclosure that protects victims' identities and allows pre-review by their legal teams.The Justice Department said the grand jury testimony largely aligned with evidence presented at Maxwell's trial. Maxwell's appeal to the Supreme Court argues that a 2007 plea agreement between Epstein and prosecutors should have protected her as well. Additionally, she recently met with Deputy Attorney General Todd Blanche about potential information she may have on other individuals.Epstein partner Maxwell opposes release of her grand jury materials | ReutersA federal judge in Boston has blocked the Trump administration from diverting over $4 billion away from a disaster prevention grant program known as Building Resilient Infrastructure and Communities (BRIC). The ruling, issued by U.S. District Judge Richard Stearns, grants a preliminary injunction to stop the government from redirecting funds intended to help state and local governments prepare for natural disasters like floods and hurricanes.The lawsuit was filed by 20 predominantly Democratic-led states, led by Massachusetts and Washington, arguing that FEMA lacked authority to cancel or repurpose the BRIC program without congressional consent. The judge agreed that the states faced potential irreparable harm and shouldn't have to wait until the funding was fully withdrawn to challenge the decision.FEMA, a part of the Department of Homeland Security, had labeled the program as wasteful and ineffective earlier this year, announcing plans to shut it down. However, Judge Stearns noted that such a move violated proper legal procedures and posed serious risks to public safety and infrastructure.The BRIC program was created in 2018 during Trump's first term and has since approved around $4.5 billion in funding for nearly 2,000 infrastructure projects, largely in coastal areas. Massachusetts Attorney General Andrea Joy Campbell said the ruling affirms the importance of federal support for community disaster preparedness.US judge blocks Trump administration from diverting disaster prevention grants | ReutersTesla and CEO Elon Musk are facing a proposed class action lawsuit from shareholders who allege they committed securities fraud by misrepresenting the safety and readiness of Tesla's self-driving technology, including the Robotaxi. The lawsuit, filed in federal court in Austin, Texas, follows a June test of the Robotaxi that revealed troubling behavior such as sudden braking, wrong-lane driving, and unsafe passenger drop-offs. After the test, Tesla's stock dropped 6.1%, erasing roughly $68 billion in market value.Shareholders argue that Musk and Tesla overstated the capabilities of their autonomous driving systems, misleading investors about the company's prospects. Key statements under scrutiny include Musk's April 2025 assertion that Tesla was "laser-focused" on launching the Robotaxi in Austin and Tesla's public claims of a scalable and safe autonomous approach. The lawsuit covers shareholders who bought stock between April 19, 2023, and June 22, 2025.Tesla CFO Vaibhav Taneja and former CFO Zachary Kirkhorn are also named as defendants. The complaint arrives as Tesla confronts lagging demand for its existing EV models and public concern over Musk's leadership and political views. Meanwhile, Tesla is appealing a recent Florida jury verdict holding it partially liable for a 2019 crash involving its self-driving software, which resulted in a $243 million damages award.Tesla, Elon Musk sued by shareholders over Robotaxi claims | ReutersThe U.S. Department of Health and Human Services (HHS), led by Secretary Robert F. Kennedy Jr., announced a sweeping rollback of government-funded mRNA vaccine projects, cutting 22 initiatives worth $500 million. The move affects high-profile organizations including Moderna, Emory University, and Tiba Biotech. Kennedy justified the decision by claiming mRNA vaccines have not effectively protected against upper respiratory illnesses like COVID-19 and influenza. He also indicated a policy pivot toward “safer, broader vaccine platforms” that could maintain effectiveness despite viral mutations.This decision marks a dramatic shift in federal vaccine policy under the Trump administration and reflects Kennedy's long-standing skepticism toward vaccine safety. It follows previous actions he's taken, including firing 17 CDC vaccine advisers, removing COVID-19 vaccines from recommended use in healthy children and pregnant women, and reducing contracts with Moderna and Novavax. The Biomedical Advanced Research and Development Authority (BARDA), which oversees U.S. pandemic preparedness, is now being redirected to focus on vaccine platforms with what the agency calls “stronger safety records” and more transparency.Critically, the rationale for these cuts leans heavily on Kennedy's controversial views, which conflict with the broader scientific consensus on the safety and efficacy of mRNA technology. While it is reasonable to assess long-term vaccine strategy, completely abandoning mRNA platforms — particularly after their role in containing the COVID-19 pandemic — appears ideologically driven rather than data-based. Public health experts warn this may jeopardize future preparedness and undercut decades of scientific advancement, especially when the HHS has not publicly released the data allegedly supporting its decision.RFK Jr. Pulls Back on mRNA Projects as Vaccine Shakeup Continues This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Guest: Komal Jhaveri, MD, FACP The second-line treatment of HR+/HER2-advanced breast cancer has evolved in recent years, particularly with the rise of biomarker-driven strategies targeting PI3Kα and other mutations. But given these advances, there's a lot we need to think about when selecting therapy, like the differences between selective and non-selective inhibitors, toxicity profiles, and shared decision-making. Joining Dr. Charles Turck to share their insights on those key considerations and how we can personalize care for patients with PI3Kα-mutated HR+/HER2- advanced breast cancer are Drs. Komal Jhaveri and Neil Iyengar. Dr. Jhaveri is the section head for the Endocrine Therapy Research Program in the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, and Dr. Iyengar is the Co-Director of the Breast Oncology Program at the Winship Cancer Institute at Emory University.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Due to their wild-type inhibition, first-generation PIK3CA inhibitors for HR+/HER2- advanced breast cancer were limited by significant toxicities, including hyperglycemia, rash, and diarrhea. But now, mutation-specific PIK3CA inhibitors could help improve tolerability and adherence as well as simplify dosing strategies—all while maintaining efficacy. To learn more about the efficacy and safety of current and emerging PIK3CA-targeted therapies, Dr. Charles Turck speaks with Dr. Neil Iyengar, Co-Director of the Breast Oncology Program and Director of Cancer Survivorship Service at Winship Cancer Institute at Emory University.

The Hidden Stress That's Sabotaging Your Body and Mind What if the real reason you're stuck, sick, or stressed isn't just your schedule—but the way your nervous system is wired to survive, not thrive? In this life-changing conversation with Dr. Sharon Bergquist—a leading internal medicine physician, researcher, and founder of the first integrative health center at Emory University—we go deep into the science of whole-person health. And I'm telling you: this will shift how you think about stress, healing, and what it really takes to feel well. Dr. Bergquist breaks down the truth about how chronic stress, trauma, and even low-grade inflammation are quietly wrecking your health behind the scenes—even when you're eating right and exercising. We're not talking about surface-level tips here. This is about the deep work that affects everything: your immune system, mental clarity, metabolism, energy, and even how fast you age. And the wild part? Most people don't even realize how much stress their body is carrying until it's already showing up as symptoms. We talk about how early childhood adversity changes your biology, why mindset alone isn't enough to heal, and how you can actually retrain your nervous system to shift out of fight-or-flight and into a state of calm, clarity, and repair. Dr. Bergquist shares practical steps you can start today—from breathwork and emotional regulation to purpose-driven habits—that work with your body, not against it. This isn't just a medical conversation—it's a blueprint for resilience. Because if you're chasing peak performance but ignoring your internal state, you're driving with the brakes on. Dr. Bergquist calls it “healthspan”—living longer and better. And that starts with how you manage your stress, how you process pain, and how you learn to feel safe in your own body again. Key Takeaways: Why chronic stress is one of the biggest threats to your long-term health How early life adversity can silently shape your health trajectory The link between emotional trauma, immune dysfunction, and aging How to activate your parasympathetic nervous system and promote healing Simple, science-backed strategies to improve your healthspan starting today The difference between treating symptoms and building true resilience If your body has been telling you something's off—or if you just know it's time to feel good again—this episode is your roadmap. — Max Out.  

My guest today is author Jack Watts. Having written thirty-four books and screenplays, including nine biographies, six of them commissioned, he received his AB from Georgia State University, his MA in Church-State Studies from Baylor University, and all but his dissertation for a PhD from Emory University. He has co-authored his newest book along with Tom David, Jr, AN AMERICAN HERO: ONE MAN'S LEGACY OF FATHERHOOD AND FAITH.  The book pays homage to Tom Davis' father, “Jimmy” Davis, who overcame impossible odds as a child after being dumped at an orphanage by his degenerate father, who he never saw again.  Pulling himself up by the bootstraps, Jimmy got an education and then sneaked into the army underage—rising through the ranks to become a WWII decorated officer—fighting in The Battle of the Bulge. But there is so much more to the story. #veteran #fatherhood #selfmade #faith #inspiration #orphan #businessman #father #lifelessons #newbook #education 

Jessica Shoemaker, professor of law at the University of Nebraska, and James Tierney, assistant professor of law at Chicago-Kent College of Law, Illinois Institute of Technology, join the Business Scholarship Podcast to discuss their article Trading Acres. This episode is hosted by Andrew Jennings, associate professor of law at Emory University, and was edited by Dean Saridakis, a law student at Emory University.

My guest today is author Jack Watts. Having written thirty-four books and screenplays, including nine biographies, six of them commissioned, he received his AB from Georgia State University, his MA in Church-State Studies from Baylor University, and all but his dissertation for a PhD from Emory University. He has co-authored his newest book along with Tom David, Jr, AN AMERICAN HERO: ONE MAN'S LEGACY OF FATHERHOOD AND FAITH.  The book pays homage to Tom Davis' father, “Jimmy” Davis, who overcame impossible odds as a child after being dumped at an orphanage by his degenerate father, who he never saw again.  Pulling himself up by the bootstraps, Jimmy got an education and then sneaked into the army underage—rising through the ranks to become a WWII decorated officer—fighting in The Battle of the Bulge. But there is so much more to the story. #veteran #fatherhood #selfmade #faith #inspiration #orphan #businessman #father #lifelessons #newbook #education 

How do states advance their national security interests? Conventional wisdom holds that states must court the risk of catastrophic war by “tying their hands” to credibly protect their interests. Dan Reiter overturns this perspective with the compelling argument that states craft flexible foreign policies to avoid unwanted wars. Through a comprehensive analysis of key international crises, including the Berlin, Taiwan Straits, and Cuban Missile Crises, and the Korean and Vietnam Wars, Reiter provides new perspectives on the causes of wars, the role of international alliances, foreign troop deployments, leader madness, and the impact of AI on international relations. With critical insights into contemporary foreign policy challenges, such as America's role in NATO, the risks of war with China, containing a resurgent Russia, and the dangers of nuclear war, Untied Hands: How States Avoid the Wrong Wars (Cambridge University Press, 2025) is essential reading for anyone interested in understanding how states can effectively manage international crises while avoiding the wrong wars. Dan Reiter is Samuel Candler Dobbs Professor of Political Science at Emory University. Leo Bader is a senior at Wesleyan University studying political theory and history. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

How do states advance their national security interests? Conventional wisdom holds that states must court the risk of catastrophic war by “tying their hands” to credibly protect their interests. Dan Reiter overturns this perspective with the compelling argument that states craft flexible foreign policies to avoid unwanted wars. Through a comprehensive analysis of key international crises, including the Berlin, Taiwan Straits, and Cuban Missile Crises, and the Korean and Vietnam Wars, Reiter provides new perspectives on the causes of wars, the role of international alliances, foreign troop deployments, leader madness, and the impact of AI on international relations. With critical insights into contemporary foreign policy challenges, such as America's role in NATO, the risks of war with China, containing a resurgent Russia, and the dangers of nuclear war, Untied Hands: How States Avoid the Wrong Wars (Cambridge University Press, 2025) is essential reading for anyone interested in understanding how states can effectively manage international crises while avoiding the wrong wars. Dan Reiter is Samuel Candler Dobbs Professor of Political Science at Emory University. Leo Bader is a senior at Wesleyan University studying political theory and history. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/political-science

How do states advance their national security interests? Conventional wisdom holds that states must court the risk of catastrophic war by “tying their hands” to credibly protect their interests. Dan Reiter overturns this perspective with the compelling argument that states craft flexible foreign policies to avoid unwanted wars. Through a comprehensive analysis of key international crises, including the Berlin, Taiwan Straits, and Cuban Missile Crises, and the Korean and Vietnam Wars, Reiter provides new perspectives on the causes of wars, the role of international alliances, foreign troop deployments, leader madness, and the impact of AI on international relations. With critical insights into contemporary foreign policy challenges, such as America's role in NATO, the risks of war with China, containing a resurgent Russia, and the dangers of nuclear war, Untied Hands: How States Avoid the Wrong Wars (Cambridge University Press, 2025) is essential reading for anyone interested in understanding how states can effectively manage international crises while avoiding the wrong wars. Dan Reiter is Samuel Candler Dobbs Professor of Political Science at Emory University. Leo Bader is a senior at Wesleyan University studying political theory and history. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/world-affairs

How do states advance their national security interests? Conventional wisdom holds that states must court the risk of catastrophic war by “tying their hands” to credibly protect their interests. Dan Reiter overturns this perspective with the compelling argument that states craft flexible foreign policies to avoid unwanted wars. Through a comprehensive analysis of key international crises, including the Berlin, Taiwan Straits, and Cuban Missile Crises, and the Korean and Vietnam Wars, Reiter provides new perspectives on the causes of wars, the role of international alliances, foreign troop deployments, leader madness, and the impact of AI on international relations. With critical insights into contemporary foreign policy challenges, such as America's role in NATO, the risks of war with China, containing a resurgent Russia, and the dangers of nuclear war, Untied Hands: How States Avoid the Wrong Wars (Cambridge University Press, 2025) is essential reading for anyone interested in understanding how states can effectively manage international crises while avoiding the wrong wars. Dan Reiter is Samuel Candler Dobbs Professor of Political Science at Emory University. Leo Bader is a senior at Wesleyan University studying political theory and history. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/chinese-studies

How do states advance their national security interests? Conventional wisdom holds that states must court the risk of catastrophic war by “tying their hands” to credibly protect their interests. Dan Reiter overturns this perspective with the compelling argument that states craft flexible foreign policies to avoid unwanted wars. Through a comprehensive analysis of key international crises, including the Berlin, Taiwan Straits, and Cuban Missile Crises, and the Korean and Vietnam Wars, Reiter provides new perspectives on the causes of wars, the role of international alliances, foreign troop deployments, leader madness, and the impact of AI on international relations. With critical insights into contemporary foreign policy challenges, such as America's role in NATO, the risks of war with China, containing a resurgent Russia, and the dangers of nuclear war, Untied Hands: How States Avoid the Wrong Wars (Cambridge University Press, 2025) is essential reading for anyone interested in understanding how states can effectively manage international crises while avoiding the wrong wars. Dan Reiter is Samuel Candler Dobbs Professor of Political Science at Emory University. Leo Bader is a senior at Wesleyan University studying political theory and history. Learn more about your ad choices. Visit megaphone.fm/adchoices

How do states advance their national security interests? Conventional wisdom holds that states must court the risk of catastrophic war by “tying their hands” to credibly protect their interests. Dan Reiter overturns this perspective with the compelling argument that states craft flexible foreign policies to avoid unwanted wars. Through a comprehensive analysis of key international crises, including the Berlin, Taiwan Straits, and Cuban Missile Crises, and the Korean and Vietnam Wars, Reiter provides new perspectives on the causes of wars, the role of international alliances, foreign troop deployments, leader madness, and the impact of AI on international relations. With critical insights into contemporary foreign policy challenges, such as America's role in NATO, the risks of war with China, containing a resurgent Russia, and the dangers of nuclear war, Untied Hands: How States Avoid the Wrong Wars (Cambridge University Press, 2025) is essential reading for anyone interested in understanding how states can effectively manage international crises while avoiding the wrong wars. Dan Reiter is Samuel Candler Dobbs Professor of Political Science at Emory University. Leo Bader is a senior at Wesleyan University studying political theory and history. Learn more about your ad choices. Visit megaphone.fm/adchoices

How do states advance their national security interests? Conventional wisdom holds that states must court the risk of catastrophic war by “tying their hands” to credibly protect their interests. Dan Reiter overturns this perspective with the compelling argument that states craft flexible foreign policies to avoid unwanted wars. Through a comprehensive analysis of key international crises, including the Berlin, Taiwan Straits, and Cuban Missile Crises, and the Korean and Vietnam Wars, Reiter provides new perspectives on the causes of wars, the role of international alliances, foreign troop deployments, leader madness, and the impact of AI on international relations. With critical insights into contemporary foreign policy challenges, such as America's role in NATO, the risks of war with China, containing a resurgent Russia, and the dangers of nuclear war, Untied Hands: How States Avoid the Wrong Wars (Cambridge University Press, 2025) is essential reading for anyone interested in understanding how states can effectively manage international crises while avoiding the wrong wars. Dan Reiter is Samuel Candler Dobbs Professor of Political Science at Emory University. Leo Bader is a senior at Wesleyan University studying political theory and history.

How do states advance their national security interests? Conventional wisdom holds that states must court the risk of catastrophic war by “tying their hands” to credibly protect their interests. Dan Reiter overturns this perspective with the compelling argument that states craft flexible foreign policies to avoid unwanted wars. Through a comprehensive analysis of key international crises, including the Berlin, Taiwan Straits, and Cuban Missile Crises, and the Korean and Vietnam Wars, Reiter provides new perspectives on the causes of wars, the role of international alliances, foreign troop deployments, leader madness, and the impact of AI on international relations. With critical insights into contemporary foreign policy challenges, such as America's role in NATO, the risks of war with China, containing a resurgent Russia, and the dangers of nuclear war, Untied Hands: How States Avoid the Wrong Wars (Cambridge University Press, 2025) is essential reading for anyone interested in understanding how states can effectively manage international crises while avoiding the wrong wars. Dan Reiter is Samuel Candler Dobbs Professor of Political Science at Emory University. Leo Bader is a senior at Wesleyan University studying political theory and history. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/book-of-the-day

You can theorise about Customer Experience all day, but gaining a Net Promoter score of 90 is not a theory. It shows a great focus and implementation of Customer Experience. This week, we are exploring how this was achieved with Kamron Kunce, VP of Marketing & Customer Experience at RJ Young. https://www.rjyoung.com/ RJ Young has been in business for over 70 years and boasts a world-class NPS score of 90+ — no small feat in today's hypercompetitive market. Kamron shares how they've transformed their Customer Experience, navigated organisational silos, and are thoughtfully introducing AI into their processes — without losing that all-important human touch. If you're wrestling with legacy systems, struggling to turn CX theory into practice, or figuring out how to scale with AI without alienating customers,  this episode is packed with practical tips you can take away today. And, if you're a regular listener, you'll know this one plays right into one of Ryan's and my favourite themes: breaking down those silos! Best Quote From the Episode “Customer Experience is everyone's responsibility. It's not just about Customer Service — it's about aligning the whole organisation around delivering value at every touchpoint.” — Kamron Kunce, RJ Young Key Takeaways ✅ CX must be a core business strategy, not a bolt-on function of Customer Service. RJ Young's “Make It Right Guarantee” puts this principle front and centre. ✅ Map your Customer Journey — and revisit it regularly. Quarterly and annual reviews keep RJ Young's CX aligned to ever-evolving customer expectations. ✅ Break down silos with transparency. Weekly cross-functional updates and quarterly company-wide video broadcasts ensure alignment across 700 employees and 9 states. ✅ Cross-functional collaboration is critical. Everyone, including Finance and HR, plays a role in the Customer Experience. ✅ Thoughtful use of AI is the future. RJ Young is leveraging AI to improve backend data insights and operational efficiency, without removing the human element that drives loyalty. ✅ CX + Culture go hand in hand. Embedding CX into your company culture is essential for sustainable success. Resources Mentioned RJ Young: https://www.rjyoung.com/  Kamron Kunce: https://www.linkedin.com/in/kamronkunce/ About the Hosts: Colin Shaw is a LinkedIn 'Top Voice' with a massive 284,000 followers and 87,000 subscribers to his 'Why Customers Buy' newsletter. Shaw is named one of the world's 'Top 150 Business Influencers' by LinkedIn. His company, Beyond Philosophy LLC, has been selected four times by the Financial Times as a top management consultancy. Shaw is co-host of the top 1.5% podcast 'The Intuitive Customer'—with over 600,000 downloads—and author of eight best-sellers on customer experience, Shaw is a sought-after keynote speaker. Follow Colin on LinkedIn. Ryan Hamilton is a Professor of Marketing at Emory University's Goizueta Business School and co-author of 'The Intuitive Customer' book. An award-winning teacher and researcher in consumer psychology, he has been named one of Poets & Quants' "World's Best 40 B-School Profs Under 40." His research focuses on how brands, prices, and choice architecture influence shopper decision-making, and his findings have been published in top academic journals and covered by major media outlets like The New York Times and CNN. His work highlights how psychology can help firms better understand and serve their customers. Ryan has a new book called “The Growth Dilemma: Managing Your Brand When Different Customers Want Different Things” Harvard Business Press 2025    Follow Ryan on LinkedIn.   Subscribe & Follow   Apple Podcasts Spotify

Hilary Allen, professor of law at American University, joins the Business Scholarship Podcast to discuss her free, serialized book FinTech Dystopia: A Summer Beach Read About Silicon Valley Ruining Things. This episode is hosted by Andrew Jennings, associate professor of law at Emory University, and was edited by Dean Saridakis, a law student at Emory University.

In this episode of "Coaching Healthcare Leaders," Dr. Lisa interviews Dr. Katrina Gipson, Assistant Professor of Emergency Medicine at Emory University and president of the Academy for Diversity and Inclusion in Emergency Medicine. Dr. Gibson shares her leadership journey, commitment to health equity, and efforts to advance diversity and inclusion in medicine. The conversation explores challenges like provider burnout, healthcare access, and systemic inequities. Dr. Gibson offers practical advice on advocacy, self-care, and boundary-setting, emphasizing the importance of rest and community support. Listeners are encouraged to pursue sustainable leadership and explore Dr. Gibson's work on health equity. You can follow more of Dr. Gipson's work by listening to her podcast Culture Shock Therapy Your Health Equity Prescription. Introduction to the Podcast (00:00:02) Dr. Lisa introduces the podcast, its mission, and previews the episode's guest and topics. Dr. Gipson's Background and Leadership Journey (00:01:30) Dr. Lisa reads Dr. Gipson's bio; Dr. Gipson shares her path into medicine and influences on her leadership. Commitment to Health Equity and Social Justice (00:03:28) Dr. Gipson discusses her motivation for pursuing health equity, her experiences as a Black woman in STEM, and resilience. Current Leadership Roles and Day-to-Day Work (00:07:37) Dr. Gipson describes her roles, especially in the Academy for Diversity and Inclusion in Emergency Medicine, and balancing clinical and academic duties. Mentorship and Building the Healthcare Pipeline (00:08:57) Focus on mentorship programs, supporting underrepresented groups, and the importance of diverse healthcare providers. Retention and Promotion in Academic Medicine (00:10:53) Challenges and strategies for retaining and promoting diverse faculty in medicine, and the importance of DEI work. Research, Education, and Advocacy in DEI (00:11:52) The role of research, education, and advocacy in reducing health inequities and empowering communities. Direct Impact on Patients and Communities (00:14:53) How Dr. Gipson's work addresses mistrust, cultural humility, and implicit bias to improve patient care and build trust. Barriers to Care: Mistrust and Social Determinants (00:15:53) Historical and ongoing reasons for mistrust in healthcare among marginalized communities and the impact on care. Suggestions for Improving Healthcare Delivery (00:19:11) Dr. Gipson's ideas for addressing burnout, staffing, and making healthcare more accessible and attractive to providers. Access Challenges and Healthcare Deserts (00:22:54) Discussion of insurance not equaling access, provider shortages, and the impact on patient outcomes. Affordability and Student Loan Forgiveness (00:24:32) The threat to public service loan forgiveness and its impact on diversity in the physician workforce. Advice for Thriving in Advocacy and Leadership (00:26:57) Dr. Gipson's tips for self-care, setting boundaries, and building supportive communities for those in advocacy roles. Closing Thoughts and Resources (00:30:06) Dr. Gipson shares information about her podcast and website; Dr. Lisa thanks her and closes the episode.

We're still making new discoveries about pregnancy. Donghai Liang, associate professor of environmental health at Emory University's Rollins School of Public Health, examines how exposure to certain chemicals may affect mothers and babies. As an exposure scientist and molecular epidemiologist, Dr. Donghai Liang is particularly interested in characterizing the human exposome and elucidating the molecular […]

Hidden Heroes (Anthem Press, 2025) offers a rare and intimate glimpse into the lives of ordinary North Koreans through a collection of short stories by renowned DPRK authors. Spanning from the 1980s to the present, these works explore the theme of the “hidden hero,” a popular moniker in the DPRK to describe the average citizen who navigates the complexities of daily life with quiet dedication for their work and country. In this interview, Dr. Kim and Dr. Berthelier discuss the appeal of North Korean literature, their approach to translating the collection, and how sharing stories reminds readers of our shared humanity. Dr. Benoit Berthelier is a senior lecturer in Korean Studies at the University of Sydney. His research interests include North Korea's cultural industries and digital technologies. View his university profile here.  Dr. Immanuel Kim is The Korea Foundation and Kim-Renaud Professor of Korean Literature and Culture Studies at George Washington University. His research focuses on the changes and development, particularly in the representations of women, sexuality, and memory, of North Korean literature from the 1960s to present day. View his university profile here.  Leslie Hickman is an Anthropology graduate student at Emory University. She has an MA in Korean Studies and a KO-EN translation certificate from the Literature Translation Institute of Korea. You can contact her at leslie.hickman@emory.edu Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Hidden Heroes (Anthem Press, 2025) offers a rare and intimate glimpse into the lives of ordinary North Koreans through a collection of short stories by renowned DPRK authors. Spanning from the 1980s to the present, these works explore the theme of the “hidden hero,” a popular moniker in the DPRK to describe the average citizen who navigates the complexities of daily life with quiet dedication for their work and country. In this interview, Dr. Kim and Dr. Berthelier discuss the appeal of North Korean literature, their approach to translating the collection, and how sharing stories reminds readers of our shared humanity. Dr. Benoit Berthelier is a senior lecturer in Korean Studies at the University of Sydney. His research interests include North Korea's cultural industries and digital technologies. View his university profile here.  Dr. Immanuel Kim is The Korea Foundation and Kim-Renaud Professor of Korean Literature and Culture Studies at George Washington University. His research focuses on the changes and development, particularly in the representations of women, sexuality, and memory, of North Korean literature from the 1960s to present day. View his university profile here.  Leslie Hickman is an Anthropology graduate student at Emory University. She has an MA in Korean Studies and a KO-EN translation certificate from the Literature Translation Institute of Korea. You can contact her at leslie.hickman@emory.edu Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/east-asian-studies

Hidden Heroes (Anthem Press, 2025) offers a rare and intimate glimpse into the lives of ordinary North Koreans through a collection of short stories by renowned DPRK authors. Spanning from the 1980s to the present, these works explore the theme of the “hidden hero,” a popular moniker in the DPRK to describe the average citizen who navigates the complexities of daily life with quiet dedication for their work and country. In this interview, Dr. Kim and Dr. Berthelier discuss the appeal of North Korean literature, their approach to translating the collection, and how sharing stories reminds readers of our shared humanity. Dr. Benoit Berthelier is a senior lecturer in Korean Studies at the University of Sydney. His research interests include North Korea's cultural industries and digital technologies. View his university profile here.  Dr. Immanuel Kim is The Korea Foundation and Kim-Renaud Professor of Korean Literature and Culture Studies at George Washington University. His research focuses on the changes and development, particularly in the representations of women, sexuality, and memory, of North Korean literature from the 1960s to present day. View his university profile here.  Leslie Hickman is an Anthropology graduate student at Emory University. She has an MA in Korean Studies and a KO-EN translation certificate from the Literature Translation Institute of Korea. You can contact her at leslie.hickman@emory.edu Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/literary-studies

Hidden Heroes (Anthem Press, 2025) offers a rare and intimate glimpse into the lives of ordinary North Koreans through a collection of short stories by renowned DPRK authors. Spanning from the 1980s to the present, these works explore the theme of the “hidden hero,” a popular moniker in the DPRK to describe the average citizen who navigates the complexities of daily life with quiet dedication for their work and country. In this interview, Dr. Kim and Dr. Berthelier discuss the appeal of North Korean literature, their approach to translating the collection, and how sharing stories reminds readers of our shared humanity. Dr. Benoit Berthelier is a senior lecturer in Korean Studies at the University of Sydney. His research interests include North Korea's cultural industries and digital technologies. View his university profile here.  Dr. Immanuel Kim is The Korea Foundation and Kim-Renaud Professor of Korean Literature and Culture Studies at George Washington University. His research focuses on the changes and development, particularly in the representations of women, sexuality, and memory, of North Korean literature from the 1960s to present day. View his university profile here.  Leslie Hickman is an Anthropology graduate student at Emory University. She has an MA in Korean Studies and a KO-EN translation certificate from the Literature Translation Institute of Korea. You can contact her at leslie.hickman@emory.edu Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/literature

Hidden Heroes (Anthem Press, 2025) offers a rare and intimate glimpse into the lives of ordinary North Koreans through a collection of short stories by renowned DPRK authors. Spanning from the 1980s to the present, these works explore the theme of the “hidden hero,” a popular moniker in the DPRK to describe the average citizen who navigates the complexities of daily life with quiet dedication for their work and country. In this interview, Dr. Kim and Dr. Berthelier discuss the appeal of North Korean literature, their approach to translating the collection, and how sharing stories reminds readers of our shared humanity. Dr. Benoit Berthelier is a senior lecturer in Korean Studies at the University of Sydney. His research interests include North Korea's cultural industries and digital technologies. View his university profile here.  Dr. Immanuel Kim is The Korea Foundation and Kim-Renaud Professor of Korean Literature and Culture Studies at George Washington University. His research focuses on the changes and development, particularly in the representations of women, sexuality, and memory, of North Korean literature from the 1960s to present day. View his university profile here.  Leslie Hickman is an Anthropology graduate student at Emory University. She has an MA in Korean Studies and a KO-EN translation certificate from the Literature Translation Institute of Korea. You can contact her at leslie.hickman@emory.edu Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/korean-studies

The payments landscape is undergoing dramatic transformation, demanding new approaches to leadership and innovation. Karen Xu, Chief Financial Officer for North America at Ingenico, brings a fresh perspective on navigating this evolution while balancing personal and professional priorities.Growing up in Shanghai's French Concession sparked Karen's curiosity to explore the world, eventually leading her to America with a full scholarship to Emory University. After building expertise at consulting powerhouses and industrial giants like GE and Honeywell, Karen made the pivotal transition to Ingenico seeking greater impact in a private equity-backed environment. Within months of joining, she transformed the North American region into the company's top performer across all financial metrics.Karen shares a defining moment when her first-grade son wished for "mommy to be happier," prompting her career pivot from a demanding global CFO role requiring 70-hour workweeks to her current position. This recalibration allowed her to maintain leadership impact while reclaiming family time - a decision she reflects on with satisfaction rather than regret.The conversation explores why payments is more welcoming to women than traditional manufacturing sectors, and why this matters when women influence 70-80% of payment decisions. Karen believes women's natural empathy, collaborative approach, and diverse perspectives drive innovation essential for the industry's future. For emerging professionals, Karen offers wisdom gained from mentors who shaped her approach to leadership: "bloom where you are planted" and develop the ability to see what others cannot. The most successful payment solutions will combine trust, ease of use, and scalability - with women leaders positioned to excel by staying close to customer needs and leveraging data insights.

Dr Christine Whelan, Consumer Science Expert at Emory University, joins Dave to talk about the declining US fertility rate.

In this JCO Article Insights episode, Michael Hughes summarizes “International Myeloma Society and International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma" by Avet-Loiseau et al. published on June 09, 2025 along with an interview with author Dr Nikhil C. Munshi, MD. TRANSCRIPT Michael Hughes: Welcome to this episode of JCO Article Insights. This is Michael Hughes, JCO's editorial fellow. Today I am interviewing Dr. Nikhil Munshi on the “International Myeloma Society and International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma” by Avet-Loiseau et al. At the time of this recording, our guest has disclosures that will be linked in the transcript. While some patients with multiple myeloma live for decades after treatment, others exhibit refractory or rapidly relapsing disease irrespective of treatment administered. We term this “high-risk myeloma.” Multiple risk stratification systems have been created, starting with the Durie-Salmon system in 1975 and evolving with the advent of novel therapeutics and novel treatment approaches. In 2015, the Revised International Staging System (R-ISS) was introduced, which incorporated novel clinical and cytogenetic markers and remained, until recently, a mainstay of risk stratification in newly diagnosed disease. Myeloma as a field has, just in the past few years, though, undergone explosive changes. In particular, we have seen groundbreaking advances not only in treatments - the introduction of anti-CD38 agents and the advent of cellular and bispecific therapies - but also in diagnostic technology and our understanding of the genetic lesions in myeloma. This has led to the proliferation of numerous trials employing different definitions of high-risk myeloma, a burgeoning problem for patients and providers alike, and has prompted attempts to consolidate definitions and terminology. Regarding cytogenetic lesions, at least, Kaiser et al's federated meta-analysis of 24 therapeutic trials, published here in the JCO in February of 2025 and recently podcasted in an interview with associate editor Dr. Suzanne Lentzsch, posited a new cytogenetic classification system to realize a shared platform upon which we might contextualize those trial results. This article we have here by Dr. Avet-Loiseau, Dr. Munshi, and colleagues, published online in early June of this year and hot off the presses, is the definitive joint statement from the International Myeloma Society (IMS) and the International Myeloma Working Group (IMWG). What is high-risk multiple myeloma for the modern era? The IMS and IMWG Genomics Workshop was held in July 2023 and was attended by international myeloma experts, collaborating to reach consensus based on large volumes of data presented and shared. The datasets included cohorts from the Intergroupe Francophone du Myélome (IFM); the HARMONY project, comprised of multiple European academic trials; the FORTE study, findings from which solidified KRd as a viable induction regimen; the Grupo Español de Mieloma Múltiple (GEM) and the PETHEMA Foundation; the German-Speaking Myeloma Multicenter Group (GMMG); the UK-based Myeloma XI, findings from which confirmed the concept of lenalidomide maintenance; Emory 1000, a large, real-world dataset from Emory University in Atlanta; the Multiple Myeloma Research Foundation Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass) dataset; and some newly diagnosed myeloma cohorts from the Mayo Clinic. Data were not pooled for analyses and were assessed individually - that is to say, with clear a priori understanding of whence the data had been gathered and for what original purposes. Consensus on topics was developed based on the preponderance of data across studies and cohorts. In terms of results, substantial revisions were made to the genomic staging of high-risk multiple myeloma, and these can be sorted into three major categories: A) alterations to the tumor suppressor gene TP53; B) translocations involving chromosome 14: t(14;16) (c-MAF overexpression), t(14;20) (MAFB overexpression), and t(4;14) (NSD2 overexpression); and C) chromosome 1 abnormalities: deletions of 1p or additional copies of 1q. In terms of category A, TP53 alterations: Deletion of 17p is present in up to 10% of patients at diagnosis and is enriched in relapsed or refractory disease. This is well-documented as a high-risk feature, but the proportion of the myeloma cells with deletion 17p actually impacts prognosis. GEM and HARMONY data analyses confirmed the use of 20% clonal cell fraction as the optimal threshold value for high-risk disease. That is to say, there must be the deletion of 17p in at least 20% of the myeloma cells on a FISH-analysis of a CD138-enriched bone marrow sample to qualify as high-risk disease. TP53 mutations can also occur. Inactivating mutations appear to have deleterious effects similar to chromosomal losses, and the biallelic loss of TP53, however it occurs, portends particularly poor prognosis. This effect is seen across Myeloma XI, CoMMpass, and IFM cohorts. Biallelic loss is rare, it appears to occur in only about 5% of patients, but next-generation sequencing is nevertheless recommended in all myeloma patients. Category B, chromosome 14 translocations: Translocation t(14;16) occurs in about 2% to 3% of patients with newly diagnosed disease. In the available data, primarily real-world IFM data, t(14;16) almost always occurs with chromosome 1 abnormalities. Translocation t(4;14) occurs in about 10% to 12% of newly diagnosed disease, but only patients with specific NSD2 alterations are, in fact, at risk of worse prognosis, which clinically appears to be about one in every three of those patients. And so together, the CoMMpass and Myeloma XI data suggest that translocation t(4;14) only in combination with deletion 1p or gain or amplification of 1q correlates with worse prognosis. Translocation t(14;20) occurs in only 2% of newly diagnosed disease. Similar to translocation t(4;14), it doesn't appear to have an effect on prognosis, except if the translocation co-occurs with chromosome 1 lesions, in which case patients do fare worse. Overall, these three translocations - t(14;16), t(4;14), and t(14;20) - should be considered high-risk only if chromosome 1 aberrations are also present. In terms of those chromosome 1 aberrations, category C, first deletions of 1p: Occurring in about 13% to 15% of newly diagnosed disease, deletion 1p eliminates critical cell checkpoints and normal apoptotic signaling. In the IFM and CoMMpass dataset analyses, biallelic deletion of 1p and monoallelic deletion of 1p co-occurring with additional copies of 1q denote high-risk. In terms of the other aberration in chromosome 1 possible in myeloma, gain or amplification of 1q: This occurs in up to 35% to 37% of newly diagnosed disease. It upregulates CKS1B, which is a cyclin-dependent kinase, and ANP32E, a histone acetyltransferase inhibitor. GEM and IFM data suggest that gain or amplification of 1q - there was no clear survival detriment to amplification - is best considered as a high-risk feature only in combination with the other risk factors as above. Now, in terms of any other criteria for high-risk disease, there remains one other item, and that has to do with tumor burden. There has been a consensus shift, really, in both the IMS and IMWG to attempt to develop a definition of high-risk disease which is based on biologic features rather than empirically observed and potentially temporally dynamic features, such as lactate dehydrogenase. Beta-2 microglobulin remains an independent high-risk indicator, but care must be taken when measuring it, as renal dysfunction can artificially inflate peripheral titers. The consensus conclusion was that a beta-2 microglobulin of at least 5.5 without renal failure should be considered high-risk but should not preclude detailed genomic profiling. So, in conclusion, the novel 2025 IMS-IMWG risk stratification system for myeloma is binary. It's either high-risk disease or standard-risk disease. It's got four criteria. Number one, deletion 17p and/or a TP53 mutation. Clonal cell fraction cut-off, remember, is 20%. Or number two, an IGH translocation - t(4;14), t(14;16), t(14;20) - with 1q gain and/or deletion of 1p. Or a monoallelic deletion of 1p with 1q additional copies or a biallelic deletion of 1p. Or a beta-2 microglobulin of at least 5.5 only when the creatinine is normal. This is a field-defining work that draws on analyses from across the world to put forward a dominant definition of high-risk disease and introduces a new era of biologically informed risk assessment in myeloma. Now, how does this change our clinical approach? FISH must be performed on CD138-enriched samples and should be performed for all patients. Next-generation sequencing should also be performed on all patients. Trials will hopefully now begin to include this novel definition of high-risk multiple myeloma. It does remain to be seen how data from novel therapeutic trials, if stratified according to this novel definition, will be interpreted. Will we find that therapies being evaluated at present have differential effects on myelomas with different genetic lesions? Other unanswered questions also exist. How do we go about integrating this into academic and then community clinical practice? How do we devise public health interventions for low-resource settings? To discuss this piece further, we welcome the esteemed Dr. Nikhil Munshi to the podcast. Dr. Munshi is a world-renowned leader in multiple myeloma and the corresponding author on this paper. As Professor of Medicine at Harvard Medical School, Director of the Multiple Myeloma Effector Cell Therapy Unit, and Director of Basic and Correlative Science at the Jerome Lipper Multiple Myeloma Center of the Dana-Farber Cancer Institute, he has presided over critical discoveries in the field.  Thank you for joining us, Dr. Munshi. Dr. Nikhil Munshi: Oh, it's my pleasure being here, Michael, to discuss this interesting and important publication. Michael Hughes: I had a few questions for you. So number one, this is a comprehensive, shall we say, monumental and wide-ranging definition for high-risk myeloma. How do you hope this will influence or impact the ways we discuss myeloma with patients in the exam room? And how do we make some of these components recommended, in particular next-generation sequencing, feasible in lower-resource settings? Dr. Nikhil Munshi: So those are two very important questions. Let's start with the first: How do we utilize this in our day-to-day patient care setting? So, as you know well, we have always tried to identify those patients who do not do so well with the current existing treatment. And for the last 30 years, what constitutes a myeloma of higher risk has continued to change with improvement in our treatment. The current definition basically centers around a quarter of the patients whose PFS is less than 2 to 3 years. And those would require some more involved therapeutic management. So that was a starting point of defining patients and the features. As we developed this consensus amongst ourselves - and it's titled as “International Myeloma Society, International Myeloma Working Group Consensus Recommendation” - this IMS-IMWG type of recommendation we have done for many years, improvising in various areas of myeloma care. Now, here, we looked at the data that was existing all across the globe, utilizing newer treatment and trying to identify that with these four-drug regimens, with transplant and some of the immunotherapy, which group of patients do not do as well. And this is where this current algorithm comes up. So before I answer your question straight, “How do we use it?” I might like to just suggest, “What are those features that we have identified?” There are four features which constitute high-risk disease in the newer definition. Those with deletion 17p with 20% clonality and/or TP53 mutation. Number two, patients with one of the translocations - t(4;14), t(14;16), or t(14;20) - co-occurring with 1q amplification or deletion 1p32. And that's a change. Previously, just the translocation was considered high-risk. Now we need a co-occurrence for it to be called high-risk. The third group is patients having biallelic deletion 1p32 or monoallelic deletion 1p32 along with 1q amplification. And finally, patients with high beta-2 microglobulin, more than or equal to 5.5 mg/dL, with normal creatinine less than 1.2 mg/dL. And the question, “How do we use this?” There are multiple areas where we incorporate high-risk features in our treatment algorithm. One of the first areas is where we would consider the induction regimen. If a patient has a high-risk disease, we would definitely consider a four-drug regimen rather than a three-drug regimen, although we are beginning to incorporate four-drug for all groups. That's one important thing. Number two, those are the patients where we do consider consolidation with transplant or maybe in the new world, considering some of the immunotherapeutic consolidation more early or more aggressively. Number three, these are the patients who get a little bit more maintenance therapy. So normally, lenalidomide might end up being our standard maintenance regimen. In patients who have high-risk disease, we incorporate either addition of daratumumab or the anti-CD38 targeting antibody and/or addition of proteasome inhibitor, either bortezomib or carfilzomib. So you would have multi-drug maintenance therapy in these patients. And in high-risk patients, we follow them with maintenance longer periods of time. One very critically important point to keep in mind is that to get the better outcome in high-risk disease, we must try to get them into MRD negativity because there is clear data that patients who do achieve MRD negativity, despite having high-risk disease, have a much superior outcome. They become near to standard-risk disease. And so, in high-risk patients, I would try to do whatever various options I have to try and get them into MRD-negative status. And when these patients relapse, we do not wait for the classic progression criteria to be met before we intervene. We would propose and suggest that we intervene earlier before the disease really blasts off. And so there are a number of areas in our setting where this high-risk definition will help us intervene appropriately and also with appropriate aggressiveness to achieve better outcome, to make this similar to standard-risk disease. Michael Hughes: Thank you, Dr. Munshi. And thoughts on how to really integrate this not only into academic centers but also lower-resource settings? Dr. Nikhil Munshi: So that's a very important question, Michael. And when we were developing this consensus, we were very cognizant of that fact. So wherever available, I think we are recommending that over a period of next 2, 3, 5 years, we should begin to switch over to sequencing-based methods because two components of this definition, one is TP53 mutation, which we cannot do without sequencing, and also reliably detecting deletion 1p requires sequencing-based method. So in the low-resource countries - and there are many in this world, and also even in our own country, patients may not be able to afford it - the older method with FISH or similar such technology, which is more affordable, is also acceptable for current time. They may miss a very small number of patients, maybe 2% to 3%, where these finer changes are not picked up, but a majority of this would be captured by them. So the current practice might still be applicable with some limitation in those patient populations, and that's what we would recommend. What is happening, fortunately, is that actually sequencing-based method is becoming cheaper. And in many centers, it is cheaper to do the sequencing rather than to do the FISH analysis. And so my hope is that even in low-resource centers, sequencing might be more economical in the end. It's, I think, the access to technology, which is a little bit limited currently, but it's hopefully becoming available soon. Michael Hughes: Thank you, Dr. Munshi. And staying for a minute and looking at the multiple myeloma subsets which might be missed by this really still very broad-ranging high-risk definition, at least by prior risk stratification systems, right, there is this group of patients who have standard-risk cytogenetics by R-ISS or R2-ISS, but they have primary refractory disease or they relapse early. We call these, as you are well aware, functionally high-risk disease. What proportion of previously FHR, functionally high-risk, myeloma patients do you expect to be captured by this novel definition? Dr. Nikhil Munshi: So I think the newer definition - and we can look at it both ways, but the newer definition should capture most of the functionally high-risk definition. To put it differently, Michael, there are patients who we know are, as you mentioned, functionally high-risk. Those are the patients who might have plasma cell leukemia, those who might have extramedullary disease, those who might not respond to our four-drug induction. If you don't respond to the four-drug induction, almost by definition, they are high-risk. However, a majority of them have one of the abnormalities that we are describing here. There would be a very small proportion which may not have. And if they do not have, we know one of the important components of this definition here is also that the genome, we know, keeps on evolving. So there may be a very small clone with the high-risk feature which was not obvious in the beginning. Following treatments or following relapse, that clone predominates, and now the patient's disease becomes high-risk.  So the definition would incorporate or would capture these functional high-risk patients, but as you said, in countries where resources are not available, using this functional high-risk would also be helpful and advantageous. Sometimes LDH ends up being a high-risk. In our studies, LDH has not come out to be high-risk anymore because the features we are describing captures most of those patients, but those alternatives, older, can still be considered if other newer techniques are not available. Michael Hughes: Got you. And in terms of these older definitions, yes, that incorporate tumor burden, these empirical observations about how myeloma presents, do you foresee any additional tumor burden indicators being added to future definitions of high-risk disease? Or do you instead see this particular definition as a major waypoint on the journey towards a fully biologically grounded definition of high-risk disease? Dr. Nikhil Munshi: I think your second part is what is going to happen. I think the tumor burden-related definition is being now replaced by the biological or genomic-based definition. And I think at some point, it will be quite fully replaced. One component not here, and it is because one thing, we don't have enough data; number two, we don't know how it will pan out, is also the influence of the microenvironment on the risk definition. For example, the immune system, the immune function, etc. But not enough data exists to suggest how it would change the current definition. So in future, would a definition be totally genomic or it could be more integrative? And my personal guess is that it would be more integrative and that some immune features might come into the picture, especially now that we are using immune-based therapy as a very important component of treatment - CAR T-cells, bispecific, and antibody-based treatments. What role the immune system plays in either supporting tumor or what role suppression of the anti-tumor immunity plays? They all will be important how patient outcomes end up being, and which in turn could translate into how patient's risk stratification might happen. So I think the older tumor burden-related definitions probably will become things of the past. What we have currently proposed and consensus developed is the new path forward, and over time, some microenvironmental influences, if defined and found to be important, may get some more incorporation if it compares favorably with the genomic features. Michael Hughes: Thank you, Dr. Munshi for that enlightening response.  To conclude the podcast, I'd like to look to the future and to the immediate future, what are the next steps for high-risk disease definition between now and discussing an integrated genomic-microenvironment-based definition? Will we see attempts to refine? Will we see a multi-level system, things like this? Dr. Nikhil Munshi: Yeah, so I think the current definition will be here to stay for the next 10 years or so. I think this has been developed using a large amount of data, so we do believe that this will remain fine. It has been validated now within the last six months by a few of the other studies. So there won't be a quick change. But we will try to, all of us will try to innovate. And as you very rightly bring up, the areas of research would include looking at the expression or transcriptomic component. Does that matter? And we do believe a small number of patients will have transcriptomic changes, not looked at the DNA changes, and may play a role. There are newer components, so long non-coding RNA, for example, is going to be an important component to look at, how it impacts the disease outcome, etc. There are also some of the proteomic-related changes which may become important in our studies. And then as we discussed, microenvironment and immunological changes. So these are the future areas of ongoing research where we all should collect data, and then in the next 5 to 10 years, we'll have another group meeting to see has anything changed or any of the features have become more important.  Most of the time, some of the older features are lost because they are not as critically high-risk, and the newer features come in. And so the historical background for just one second, there was a time when chromosome 13 was considered a high-risk disease. We now don't even mention it because it's not high-risk. The newer treatments have improved the outcome. t(4;14) used to be a high-risk disease. Now by itself today, in this definition by itself is not; it needs to be with something else. And so I think this is a great sign of progress. As we improve the treatment and outcomes, some of the features will become less important, new features will come up, and we'll need to keep on evolving with time and with technology and make it better for patients. Michael Hughes: Thank you so much, Dr. Munshi, for your wisdom, for your sagacity, for your historical perspective as well.  Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries. And be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Send us a textWhen Jesus' disciples asked, "Lord, teach us to pray," they recognized how Jesus connected with the Divine. The prayer the disciples asked for wasn't about polished words. It was about relationship. In this episode, Melissa has a conversation with The Rev. Canon Salmoon Bashir about prayer and its power to transform our spiritual lives. Salmoon shares the story of how his mother instilled prayer as a non-negotiable daily practice in their family life. The conversation reveals how early formation in prayer creates patterns that sustain us through life's complexities.Prayer emerges not as a performance or obligation but as relationship-building with the divine. "The focus of prayer is to be like Jesus, love like Jesus, pray like Jesus, forgive like Jesus, welcome strangers like Jesus," Salmoon explains. This relational approach dismantles the anxiety many feel about "praying correctly," affirming that from ancient liturgical traditions to simple heartfelt words, there's no wrong way to pray. As Salmoon prepares to pass these prayer traditions to his four-month-old son by reading Psalms at bedtime, we're reminded that prayer forms not just our spiritual lives but the generations that follow. Listen in for the full conversation.Read For Faith, the companion devotional.The Rev. Canon Salmoon Bashir serves as the Canon for Liturgy and Ecumenism at the Cathedral of St. Philip. Originally from Pakistan, Salmoon brings over a decade of experience in offering compassionate and thoughtful leadership across multicultural, multi-faith contexts in the United States, Pakistan, Iraq, the United Kingdom, and the Republic of Georgia.Before ordained ministry, Salmoon worked as a Project Engineer in the oil and gas industry in the Middle East. Responding to a vocational call, he joined the Community of St. Anselm at Lambeth Palace in London, serving alongside the Archbishop of Canterbury. He later moved to the Republic of Georgia, where he served as Assistant Pastor in a vibrant, multiethnic, and multidenominational church.Salmoon's call to the priesthood in The Episcopal Church led him to Atlanta, where he earned a Master of Divinity degree with a Certificate in Episcopal-Anglican Studies and a Chaplaincy concentration from Emory University's Candler School of Theology. In addition to his ministry, Salmoon serves on several academic, religious, and nonprofit boards. He is married to Mari, a fellow graduate of Candler School of Theology, who works with a faith-based nonprofit organization. Support the show Follow us on IG and FB at Bishop Rob Wright.

Sasha Debevec-McKenney joins Kevin Young to read “Hammond B3 Organ Cistern,” by Gabrielle Calvocoressi, and her own poem “Kaepernick.” Debevec-McKenney is the author of the new poetry collection “Joy Is My Middle Name.” She was a Jay C. and Ruth Halls Poetry Fellow at the University of Wisconsin, and a creative-writing fellow at Emory University. Her poems have been published widely. Learn about your ad choices: dovetail.prx.org/ad-choices

Kimberly Belflower is a playwright and educator originally from a small town in Appalachian Georgia. This is her Broadway debut, and she's probably crying about it right now. Plays include JOHN PROCTOR IS THE VILLAIN (2024 Huntington Theatre, 2022 Studio Theatre, 2019 Kilroys List, published by Broadway Licensing, Farm Theatre College Collaboration Project); LOST GIRL (2018 Milwaukee Repertory Theatre, Kennedy Center Darrell Ayers National Playwriting Award, published by Concord Theatricals); and SAINT PIGTAIL (commissioned and developed by Studio Theatre, 2023 O'Neill Finalist). Kimberly has worked with South Coast Rep, Manhattan Theatre Club, Alliance Theatre, Ojai Playwrights Conference, among others. She was also a narrative lead at Meow Wolf, where she wrote a short film with original music by Beach House. Kimberly proudly holds an MFA from the University of Texas at Austin and teaches playwriting at Emory University in Atlanta. Gabriel Eber - Broadway: Matilda The Musical (Tony Winner, Featured Actor), Pass Over, Casa Valentina, Brief Encounter, Time And The Conways, Therese Raquin, Red. Off-Broadway: 4000 Miles (OBIE Winner), Preludes, Gently Down The Stream, Sally & Tom, Peer Gynt, Prometheus Bound. Film/TV: News Of The World, “Dickinson,” I Am A Seagull, “Mr. Mercedes,” Ricki And The Flash, The Immortal Life Of Henrietta Lacks, and the upcoming Dope Thief. As a singer, he's performed at Carnegie Hall, Royal Albert Hall and with the New York Philharmonic. Fina Strazza - Broadway: Matilda in Matilda the Musical. Off-Broadway: Animal, A Loss of Roses, Member of the Wedding. TV: “Paper Girls” (series lead), “Law and Order: SVU” (recurring), “Madam Secretary,” “FBI: Most Wanted” “Last Week Tonight.” A student at NYU's Tisch, her eight films include Above the Shadows, A Christmas Melody (recording “Oh, Santa!” with director Mariah Carey), and Netflix's upcoming “Fear Street: Prom Queen.” Learn more about your ad choices. Visit podcastchoices.com/adchoices

Adam Callister, a JD/PhD student at Yale University; Andrew Granato, also a JD/PhD student at Yale University; and Belisa Pang, an assistant professor of law at the University of Michigan, join the Business Scholarship Podcast to discuss their article Expert Asymmetry: Evidence from Securities Litigation. This episode is hosted by Andrew Jennings, associate professor of law at Emory University, and was edited by Dean Saridakis, a law student at Emory University.

In this episode of The Intuitive Customer, Colin Shaw speaks with Andy Traba, VP of Product Marketing at NICE, about the company's new mission: Creating a NiCE World. This isn't just a rebranding message — it's a strategic shift toward unified, proactive, and AI-enabled customer experiences. Andy and Colin explore why AI alone isn't enough, the dangers of siloed implementations, and why leading organizations are turning to platforms — not point solutions — to orchestrate connected, emotionally resonant journeys. If your organization is serious about CX transformation, this conversation provides clear guidance on where to start, what to avoid, and how to align internal functions toward a shared customer strategy. Quote of the Episode “The moment you find success with AI, you'll want more. That's why you have to start with a platform — not a point solution — so your entire organization can scale, align, and deliver a truly connected experience.” — Andy Traba, VP of Product Marketing, NiCE